市場調查報告書
商品編碼
1497590
製藥業人工智慧市場:按產品、技術、應用和最終用戶分類 - 2024-2030 年全球預測Artificial Intelligence in Pharmaceutical Market by Offering (Hardware, Services, Software), Technology (Computer Vision, Context-Aware Computing, Machine Learning), Applications, End-users - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年人工智慧在製藥領域的市場規模為162.1億美元,預計2024年將達到207.6億美元,2030年將達到973.5億美元,複合年成長率為29.18%。
製藥市場中的人工智慧(AI)是指將先進的機器學習演算法、自然語言處理和資料分析技術整合到全球製藥業的藥物發現、開發和製造過程中。為了改善治療效果而對個人化醫療的需求不斷成長,以及基因組學和高通量技術的進步產生了大量複雜的資料,需要先進的分析技術。然而,用於訓練機器學習模型的精選資料集的可用性有限,阻礙了人工智慧在醫學中的採用。然而,將巨量資料分析與人工智慧結合還可以提高我們對各種疾病分子機制的理解,並確定可能成為未來藥物標靶的新型生物標記。
主要市場統計 | |
---|---|
基準年[2023] | 162.1億美元 |
預測年份 [2024] | 207.6億美元 |
預測年份 [2030] | 973.5億美元 |
複合年成長率(%) | 29.18% |
區域洞察
在美國,由於先進技術的早期採用和政府的支援政策,醫藥人工智慧市場的環境正在改善。美國擁有多家領先的人工智慧新興企業,它們利用人工智慧進行藥物發現、分子建模、臨床試驗最佳化和個人化醫療。在美國,大型製藥企業正在與人工智慧主導的新興企業合作,並大力投資研究,以加速藥物發現和開發。在歐洲地區,法國、德國、英國等國紛紛推出國家戰略,推動人工智慧在醫藥等各產業的應用。儘管與其他地區相比進展緩慢,但中東國家正在透過人工智慧投資取得進展。非洲的潛力在於透過其不斷發展的製藥生態系統來應對其獨特的醫療保健挑戰。在亞太地區,以中國、日本和印度為首的利用人工智慧的藥物方面取得了顯著的進展。此外,公共和私人對製藥基礎設施的投資不斷增加,為引入人工智慧創造了積極的環境。
FPNV定位矩陣
FPNV 定位矩陣對於評估製藥市場人工智慧供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對製藥市場人工智慧供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析也為該領域的競爭性質提供了寶貴的見解,包括累積研究期、片段化優勢和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對人工智慧在製藥市場中的當前地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[189 Pages Report] The Artificial Intelligence in Pharmaceutical Market size was estimated at USD 16.21 billion in 2023 and expected to reach USD 20.76 billion in 2024, at a CAGR 29.18% to reach USD 97.35 billion by 2030.
Artificial intelligence (AI) in the pharmaceutical market refers to integrating advanced machine learning algorithms, natural language processing, and data analytics technologies into the drug discovery, development, and manufacturing processes of the global pharmaceutical industry. The growing demand for personalized medicine to improve treatment outcomes and advancements in genomics and high-throughput technologies generate large volumes of complex data requiring advanced analytical techniques. However, the limited availability of curated datasets for training machine learning models hinders the adoption of AI in pharmaceuticals. Nevertheless, integrating big data analytics with AI may also facilitate a better understanding of molecular mechanisms underlying various diseases or identify novel biomarkers that could be targets of future drugs; this further creates lucrative opportunities for the market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 16.21 billion |
Estimated Year [2024] | USD 20.76 billion |
Forecast Year [2030] | USD 97.35 billion |
CAGR (%) | 29.18% |
Regional Insights
America provides an improved landscape for the AI in pharmaceutical market with an early adoption of advanced technologies and supportive government policies. The United States is home to several leading AI startups leveraging AI for drug discovery, molecular modeling, clinical trials optimization, and personalized medicine. In the U.S., major pharmaceutical firms are partnering with AI-driven startups and investing heavily in research to expedite drug discovery and development. In the European region, countries such as France, Germany, and the United Kingdom have introduced national strategies propelling AI applications across industries, including pharmaceuticals. Although slower in comparison to other regions, Middle Eastern countries are advancing through investment in AI. Africa's potential lies in addressing unique healthcare challenges through its developing pharma ecosystem. The Asia Pacific region showcases significant growth in AI-driven pharmaceutical advancements with China, Japan, and India at the forefront. In addition, increasing public-private investments in pharmaceutical manufacturing infrastructure provides a positive landscape for AI deployments.
Market Insights
The market dynamics represent an ever-changing landscape of the Artificial Intelligence in Pharmaceutical Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Artificial Intelligence in Pharmaceutical Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Artificial Intelligence in Pharmaceutical Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery
Merck entered into two new strategic collaborations in the field of drug discovery. These collaborations, with BenevolentAI and Exscientia, aim to utilize Artificial Intelligence (AI)-driven design and discovery capabilities to generate innovative drug candidates for clinical development in areas including oncology, neurology, and immunology. [Published On: 2023-09-20]
Launch of Insilico's Phase II Program Highlights Generative AI Momentum
Insilico Medicine has recently initiated Phase II clinical trials for a groundbreaking drug, INS018_055, developed using generative artificial intelligence in pharmaceuticals. This drug has received Orphan Drug certificate from the FDA and aims to treat idiopathic pulmonary fibrosis (IPF). The utilization of artificial intelligence has significantly accelerated the drug development process for Insilico. Insilico has formed partnerships with several biopharma companies for AI-based drug development projects. [Published On: 2023-08-14]
Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine
Google Cloud introduced two AI-powered solutions for the life sciences industry. These solutions aim to enhance drug discovery and precision medicine for biotechnology companies, pharmaceutical firms, and public sector organizations. The first solution called the Target and Lead Identification Suite, helps researchers gain a better understanding of amino acids' function and predict protein structure. The second solution, known as the Multiomics Suite, expedites the discovery and interpretation of genomic data. [Published On: 2023-05-16]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Artificial Intelligence in Pharmaceutical Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Artificial Intelligence in Pharmaceutical Market, highlighting leading vendors and their innovative profiles. These include AiCure, LLC, Aspen Technology Inc, Atomwise Inc, BenevolentAI SA, BioSymetrics Inc., BPGbio Inc., Butterfly Network, Inc., Cloud Pharmaceuticals, Inc., CloudMedX Inc., Cyclica Inc, Deargen Inc, Deep Genomics Incorporated, Euretos Services BV, Exscientia plc, Google LLC, Insilico Medicine, Intel Corporation, International Business Machines Corporation, InveniAI LLC, Isomorphic Labs, Microsoft Corporation, Novo Nordisk A/S, Oracle Corporation, Sanofi SA, Turbine Ltd., Viseven Europe OU, and XtalPi Inc..
Market Segmentation & Coverage